Most-Upgraded StocksMost-UpgradedNASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $138.94 -0.55 (-0.39%) Closing price 04:00 PM EasternExtended Trading$138.96 +0.02 (+0.01%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neurocrine Biosciences Stock (NASDAQ:NBIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$137.00▼$140.6350-Day Range$139.49▼$185.5052-Week Range$122.14▼$186.12Volume1.14 million shsAverage Volume1.20 million shsMarket Capitalization$14.12 billionP/E Ratio20.37Dividend YieldN/APrice Target$201.09Consensus RatingModerate Buy Company Overview Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company develops therapies for conditions with significant unmet medical needs, using expertise in neuroscience and endocrine biology. Its primary commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. Neurocrine also has a pipeline of investigational therapies targeting disorders such as schizophrenia, major depressive disorder, Parkinson’s disease, congenital adrenal hyperplasia and other neurological or endocrine conditions. Founded in 1992 and headquartered in San Diego, California, Neurocrine serves patients primarily through the U.S. market while advancing additional programs through collaborations and international partnerships. Kyle Gano serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreNBIX MarketRank™: Neurocrine Biosciences scored higher than 95% of companies evaluated by MarketBeat, and ranked 15th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 19 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialNeurocrine Biosciences has a consensus price target of $201.09, representing about 44.7% upside from its current price of $138.94.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth30.30% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 30.30% in the coming year, from $7.26 to $9.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 20.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 20.37, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.73.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.21% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 4.65.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 11.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.04 News SentimentNeurocrine Biosciences has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,611,976.00 in company stock.Percentage Held by Insiders4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Stock News HeadlinesRBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform RatingSeptember 21 at 8:16 PM | finance.yahoo.comMatt Abernethy Sells 2,311 Shares of Neurocrine Biosciences (NASDAQ:NBIX) StockSeptember 17, 2026 | americanbankingnews.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 24 at 1:00 AM | Stansberry Research (Ad)David Boyer Sells 826 Shares of Neurocrine Biosciences (NASDAQ:NBIX) StockSeptember 16, 2026 | insidertrades.comNeurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comMorgan Stanley Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $183.00September 13, 2026 | americanbankingnews.comNeurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comNeurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $141.83 at the beginning of 2026. Since then, NBIX stock has decreased by 2.0% and is now trading at $138.94. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Friday, July, 31st. The company reported $2.85 EPS for the quarter, topping analysts' consensus estimates of $1.65 by $1.20. The firm's revenue was up 39.5% compared to the same quarter last year. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' board authorized a stock repurchase program on Friday, February 21st 2025, which permits the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could buy up to 4.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional shareholders include BlackRock Inc. (13.49%), Bank of New York Mellon Corp (0.69%), Ieq Capital LLC (0.63%) and Bank of America Corp DE (0.61%). Insiders that own company stock include Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Darin Lippoldt, Matt Abernethy, Eric Benevich, William H Rastetter, Richard F Pops, Jude Onyia, Eiry Roberts, Julie Cooke, Ingrid Delaet, Stephen A Sherwin, David W Boyer and Shalini Sharp. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2026Today9/24/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 2 days ago, NBIX's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees2,000Year Founded1992Price Target and Rating Average Price Target for Neurocrine Biosciences$201.09 High Price Target$253.00 Low Price Target$160.00 Potential Upside/Downside+44.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$6.82 Trailing P/E Ratio20.37 Forward P/E Ratio19.14 P/E Growth0.66Net Income$478.60 million Net Margins20.91% Pretax Margin27.87% Return on Equity22.43% Return on Assets15.64% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.75 Sales & Book Value Annual Sales$3.37 billion Price / Sales4.19 Cash Flow$4.90 per share Price / Cash Flow28.38 Book Value$32.63 per share Price / Book4.26Miscellaneous Outstanding Shares101,649,000Free Float96,973,000Market Cap$14.12 billion OptionableOptionable Beta0.38 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NBIX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
